Otrivine Blocked Nose Relief, 0.1% w/v Nasal Spray, Solution

Summary of Product Characteristics Updated 13-Nov-2026 | Haleon UK Trading Limited

1. Name of the medicinal product

Otrivine Sinusitis Relief, 0.1% w/v Nasal Spray, Solution

Otrivine Blocked Nose Relief, 0.1% w/v Nasal Spray, Solution

Otrivine Allergy Relief, 0.1% Nasal Spray

2. Qualitative and quantitative composition

Active ingredient: 0.1% wlv Xylometazoline Hydrochloride

For excipients see 6.1

3. Pharmaceutical form

Nasal spray, solution (Nasal Spray)

A clear, colourless solution

4. Clinical particulars
4.1 Therapeutic indications

For the symptomatic relief of nasal congestion, perennial and allergic rhinitis (including hay fever), sinusitis.

4.2 Posology and method of administration

By intranasal administration using nasal spray.

Adults and children 12 years and above: 1 spray into each nostril 1-3 times a day as required, for a maximum of 5 days. Maximum daily use: no more than 3 doses should be given in any 24 hours.

Not suitable for children under 12 years.

Laterally actuated pump (Khone): The laterally actuated metered-dose spray ensures that the solution is well distributed over the surface of the nasal mucosa by spraying a fine mist.

Before using for the first time, prime the pump by actuating 5 times. Once primed, the pump will normally remain charged throughout regular daily treatment periods. If the spray is not ejected during the full actuation stroke, or if the product has not been used for longer than 7 days, the pump will need to be re-primed with 2 actuations.

Vertically actuated pump (Freepod): Before the first application, prime the pump by actuating 4 times. Once primed, the pump will normally remain charged throughout regular daily treatment periods. If the spray is not ejected during the full actuation stroke, or if the product has not been used for longer than 7 days, the pump will need to be reprimed with 4 actuations.

The recommended dose should not be exceeded, especially in children and the elderly.

Leave at least 8 hours between doses, unless otherwise advised by your doctor or healthcare professional.

Do not exceed the recommended dose. Do not use for more than 5 consecutive days.

Continuous use of the product for more than 5 days can lead to an increased risk of side effects (see section 4.4).

Medical advice should be sought if symptoms of nasal congestion persist or worsen or do not improve after 5 days as alternative treatment may be required.

4.3 Contraindications

Known hypersensitivity to xylometazoline.

Do not take with other sympathomimetic decongestants.

Patients with trans-sphenoidal hypophysectomy or surgery exposing the dura mater.

Narrow-angle glaucoma.

Rhinitis sicca or atrophic rhinitis.

Otrivine 0.1% is contraindicated in children aged less than 12 years.

Use in people with phaeochromocytoma, prostatic hypertrophy or those receiving monoamine oxidase inhibitors (MAOI) treatment or who have received them in the last two weeks.

4.4 Special warnings and precautions for use

This medicine is intended for short-term use only. Repeated and/or prolonged administration can cause appreciable systemic exposure to the active substances and increase the risk of side effects.

Tachyphylaxis – a rapidly diminishing response to the drug after a few doses.

Using more of this product and/or using it for longer than recommended may also lead to reduced effect of a dose (due to repetitive drug exposure) and rebound congestion (see 4.8).

Prolonged or excessive use may result in reactive hyperaemia, chronic swelling of the nasal mucosa known as rhinitis medicamentosa, and atrophy of the nasal mucosa. Increasing the dose and/or frequency of xylometazoline nasal spray at onset of rebound congestion and/or rhinitis medicamentosa, will worsen the nasal congestion. Patients must stop treatment rather than increasing the dose or prolonging treatment. It is necessary to ensure that the treatment period does not exceed 5 days of continuous use. Alternative treatment may be required if nasal congestion persists beyond the recommended treatment period (see 4.8).

Otrivine, like other preparations belonging to the same class of active substances, should be used only with caution in patients showing a strong reaction to sympathomimetic agents as evidenced by signs of insomnia, dizziness, tremor, cardiac arrhythmias or elevated blood pressure.

Caution is recommended in patients with hypertension, cardiovascular disease, hyperthyroidism, diabetes mellitus or tri and tetra-cyclic antidepressant treatment (see Interactions).

Patients with long QT syndrome treated with xylometazoline may be at increased risk of serious ventricular arrhythmias.

Keep medicines out of the sight and reach of children.

Information concerning excipients

Otrivine contains benzalkonium chloride. This may cause irritation of the nasal mucosa.

Labelling (outer pack):

The label will state (to be displayed prominently on the front of the outer pack):

For 5 days use only.

The label will also state:

Leave at least 8 hours between doses.

For short-term use only.

Do not use for more than 5 days in a row. Do not use more medicine than the label tells you to. If your symptoms worsen or you do not feel better after 5 days, stop treatment and seek medical advice.

4.5 Interaction with other medicinal products and other forms of interaction

The concomitant use of xylometazoline with monoamine oxidase (MAO) inhibitors or tri- and tetra-cyclic antidepressants, may cause an increase in blood pressure due to the cardiovascular effects of these substances (see Contraindications).

4.6 Fertility, pregnancy and lactation

No foetal toxicity or fertility studies have been carried out in animals. In view of its potential systemic vasoconstrictor effect, it is advisable to take the precaution of not using Otrivine during pregnancy.

No evidence of any adverse effect on the breast-fed infant. However, it is not known if xylometazoline is excreted in breast milk, therefore caution should be exercised and Otrivine should be used only on the advice of a doctor whilst breastfeeding.

4.7 Effects on ability to drive and use machines

Otrivine has no or negligible influence on the ability to drive and use machines.

4.8 Undesirable effects

The adverse effects listed below are classified by system organ class and frequency according to the following convention: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000) or very rare (<1/10,000).

MeDRA SOC

Adverse reaction

Frequency

Immune System Disorders

Hypersensitivity reaction (angioedema, rash, pruritus)

Very rare

Nervous System Disorders

Headache

Common

Eye Disorders

Transient visual impairment

Very rare

Cardiac Disorders

Heart rate irregular

Heart rate increased

Very rare

Very rare

Respiratory, thoracic and mediastinal disorders

Nasal Dryness

Nasal Discomfort

Epistaxis

Common

Common

Uncommon

Gastrointestinal disorders

Nausea

Common

General disorders and administration site

Application site burning

Common

Tachyphylaxis (see 4.4)

Tolerance with diminished effect, especially with prolonged or heavy use (see 4.4)

Rebound congestion (see 4.4)

Rhinitis medicamentosa (see 4.4)

Not Known

Other side effects include:

 • A burning sensation in the nose and throat

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App store.

4.9 Overdose

Symptoms and Signs

Excessive administration of topical xylometazoline hydrochloride or accidental ingestion may cause severe dizziness, perspiration, severely lowered body temperature, headache, bradycardia, hypertension, respiratory depression, coma and convulsions. Hypertension may be followed by hypotension. Small children are more sensitive to toxicity than adults.

Treatment

Appropriate supportive measures should be initiated in all individuals suspected of an overdose, and urgent symptomatic treatment under medical supervision is indicated when warranted. This would include observation of the individual for several hours.

5. Pharmacological properties
5.1 Pharmacodynamic properties

Otrivine Adult Measured Dose Sinusitis Spray is a sympathomimetic agent with marked alpha-adrenergic activity, and is intended for use in the nose. It constricts the nasal blood vessels, thereby decongesting the mucosa of the nose and neighbouring regions of the pharynx. This enables patients suffering from colds to breathe more easily through the nose. The effect of Otrivine Adult Measured Dose Sinusitis Spray begins within a few minutes and lasts for up to 10 hours. Otrivine Adult Measured Dose Sinusitis Spray is generally well tolerated and does not impair the function of ciliated epithelium.

In a double-blind, saline solution (Otrisal) controlled study in patients with common cold, the decongestant effect of Otrivine was significantly superior (p<0.0001) to Otrisal saline solution based on rhinomanometry measurement at 1 hour after administration of the study drugs.

5.2 Pharmacokinetic properties

Systemic absorption may occur following nasal application of xylometazoline hydrochloride solutions. It is not used systemically.

5.3 Preclinical safety data

Not applicable.

6. Pharmaceutical particulars
6.1 List of excipients

Benzalkonium chloride

Disodium phosphate dodecahydrate (Sodium phosphate)

Disodium edetate

Sodium dihydrogen phosphate dihydrate (Sodium acid phosphate)

Sodium chloride

Sorbitol

Hypromellose

Purified water

6.2 Incompatibilities

None

6.3 Shelf life

36 months

After first opening, the nasal spray can be used until the end of the shelf-life.

6.4 Special precautions for storage

Freepod: No special precautions.

Khone: Do not store above 30°C.

6.5 Nature and contents of container

High density polyethylene bottle with a vertically actuated polypropylene/polyethylene metered dose pump (materials in contact with the solution: low density polyethylene, high density polyethylene, polyethylene/butyl, stainless steel) and a polypropylene nozzle with a protective cap in a cardboard carton.

Or

High density polyethylene bottle with a laterally actuated metered dose pump (materials in contact with product: low density polyethylene/polyethylene compound, lubricant, stainless steel, polydimethyl-siloxane, PTFE/PET layer) with a polypropylene nozzle with protective cap.

Pack size 10 ml.

6.6 Special precautions for disposal and other handling

Medicines should be kept out of the reach of children.

7. Marketing authorisation holder

Haleon UK Trading Limited,

The Heights,

Weybridge,

Surrey,

KT13 0NY,

U.K.

8. Marketing authorisation number(s)

PL 44673/0184

9. Date of first authorisation/renewal of the authorisation

1st October 1997/19TH August 2010

10. Date of revision of the text

10th November 2026

Company Contact Details
Haleon UK Trading Limited
Address

The Heights, Weybridge, Surrey, KT13 0NY, UK

Customer Care direct line

0800 783 8881

WWW

https://www.haleon.com/

Medical Information e-mail
Medical Information Direct Line

0800 783 8881